Abstract: A rapid real-time visualization system for a crack initiation process of a concrete component includes a pressure test machine, a fluorescent solution spraying device, an ultraviolet lamp group, a visible light imaging device group and a computer control system. Before the concrete component cracks, a surface of the concrete component is coated with a fluorescent solution retention layer to separate the sprayed fluorescent excitation solution from the concrete component, making the fluorescent excitation solution adhere to the fluorescent solution retention layer for a long time to mark cracks at any position in real time. The rapid real-time visualization system is used to achieve visualization of the crack initiation process, especially an early stage thereof. The rapid real-time visualization system and method can be used to study patterns of microcrack mutual traction development and aggregation into groups when concrete materials crack at any position or multiple points at a component scale.

Abstract: Example embodiments are directed to systems and methods for providing end of route navigation. In example embodiments, a network system identifies a destination of a route and retrieves a display template based on the destination. The display template provides guidelines for display of end of route content, whereby the display of the end of the route content is different than display of content during a middle of the route. The network system identifies, based on the display template, a display time to trigger the display of the end of the route content. The display time may be associated with a threshold distance to the destination. The network system monitors a location of a vehicle along the route and accesses end of route content. Responsive to detecting that the location of the vehicle is at the threshold distance to the destination, the network system causes presentation of the end of the route content on a device associated with the vehicle.

Abstract: Example embodiments are directed to systems and methods for providing end of route navigation. A network system identifies a destination of a route and retrieves a display template based on the destination. The display template provides guidelines for display of end of route content, whereby the display of the end of the route content is different than display of content during a middle of the route. Based on the display template, a display time to trigger display of the end of the route content. The display time may be associated with a threshold distance to the destination. The network system monitors a location of a vehicle along the route and accesses end of route content. Responsive to detecting that the location of the vehicle is at the threshold distance to the destination, the end of the route content is displayed on a device associated with the vehicle.

Abstract: A method for hepatocellular carcinoma (HCC) subtype classification and treatment may include identifying, for a liver epithelial cell lineage, one or more features associated with the liver epithelial cell lineage. The one or more features may be designated as representative of a molecular subtype associated with hepatocellular carcinoma (HCC) such as, for example, a cholangio-like subtype, a hepatocyte-like subtype, or a progenitor-like subtype. A patient may be determined to exhibit the molecular subtype if these features are detected within the tumor sample of the patient. Moreover, treatment for the patient may be determined based on the molecular subtype exhibited by the patient. For example, treatment for the patient may include additional therapies, such as an GPC3/CD3 bi-specific antibody, to overcome subtype-specific resistance to combination immunotherapy associated with the progenitor-like subtype. Related systems and computer program products are also provided.

Abstract: A rapid real-time visualization system for a crack initiation process of a concrete component includes a pressure test machine, a fluorescent solution spraying device, an ultraviolet lamp group, a visible light imaging device group and a computer control system. Before the concrete component cracks, a surface of the concrete component is coated with a fluorescent solution retention layer to separate the sprayed fluorescent excitation solution from the concrete component, making the fluorescent excitation solution adhere to the fluorescent solution retention layer for a long time to mark cracks at any position in real time. The rapid real-time visualization system is used to achieve visualization of the crack initiation process, especially an early stage thereof. The rapid real-time visualization system and method can be used to study patterns of microcrack mutual traction development and aggregation into groups when concrete materials crack at any position or multiple points at a component scale.

Abstract: The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a lung cancer; a cervical cancer; a breast cancer; a head and neck cancer; a liver cancer; a bladder cancer; a gastric cancer; an esophageal cancer; a pancreatic cancer; a kidney or renal cancer; a melanoma; an ovarian cancer; or a colorectal cancer). More specifically, the invention concerns the treatment of patients having cancer with an anti-TIGIT antagonist antibody, including treatment with an anti-TIGIT antagonist antibody in a combination therapy.

Abstract: Provided herein are devices for utilizing vibrational strong coupling (VSC) in a chemical reaction comprising a reaction chamber defined in a housing, at least one inlet for introducing one or more reactants into the reaction chamber, at least one outlet for removing one or more reactants and/or one or more reaction products form the reaction chamber, and a window defined on opposed first and second sides of the housing and comprising a material which does not strongly absorb infrared radiation and arranged such that infrared radiation directed from a source outside of the housing can enter into the reaction chamber. Also provided are methods of modifying chemical reactions as well as catalyzing chemical reactions.

Abstract: A machine-learning model (e.g., a clustering model) may be used to predict a phenotype of a tumor based on expression levels of a set of genes. The set of genes may have been identified using a same or different machine-learning model. The phenotype may include an immune-excluded, immune-desert or an inflamed/infiltrated phenotype. A treatment strategy and/or treatment recommendation may be identified based on the predicted phenotype.

Abstract: This application discloses methods of designing a treatment protocol for a human patient with ovarian cancer, as well as methods of treatment of ovarian cancer. This application also includes methods of characterizing an ovarian cancer in a human patient by the type of tumor.

Abstract: A machine-learning model (e.g., a clustering model) may be used to predict a phenotype of a tumor based on expression levels of a set of genes. The set of genes may have been identified using a same or different machine-learning model. The phenotype may include an immune-excluded, immune-desert or an inflamed/infiltrated phenotype. A treatment strategy and/or treatment recommendation may be identified based on the predicted phenotype.

Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., a bladder cancer (e.g., UC, e.g., mUC), a kidney cancer, a lung cancer, a liver cancer, an ovarian cancer, a pancreatic cancer, a colorectal cancer, or a breast cancer). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of identifying an individual having a cancer who may benefit with an anti-cancer therapy that includes an immunotherapy (e.g., a PD-L1 axis binding antagonist such as an anti-PD-L1 antibody (e.g., atezolizumab)) and a suppressive stromal antagonist (e.g.

Abstract: The present invention relates to methods and kits or articles of manufacture related thereto that may find use, inter alia, in assessing responsiveness of cancers to MUC16 antagonists by monitoring HE4 expression. In some embodiments, the methods include measuring the level of expression of HE4 in a sample from a subject; comparing the level of expression of HE4 in the sample with the level of expression of HE4 in a sample previously obtained from the subject; and, optionally, administering to the subject a therapeutically effective amount of a MUC16 antagonist.

Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., a bladder cancer (e.g., UC, e.g., mUC), a kidney cancer, a lung cancer, a liver cancer, an ovarian cancer, a pancreatic cancer, a colorectal cancer, or a breast cancer). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of identifying an individual having a cancer who may benefit with an anti-cancer therapy that includes an immunotherapy (e.g., a PD-L1 axis binding antagonist such as an anti-PD-L1 antibody (e.g., atezolizumab)) and a suppressive stromal antagonist (e.g.

Abstract: The present invention relates to methods and kits or articles of manufacture related thereto that may find use, inter alia, in assessing responsiveness of cancers to MUC16 antagonists by monitoring HE4 expression. In some embodiments, the methods include measuring the level of expression of HE4 in a sample from a subject; comparing the level of expression of HE4 in the sample with the level of expression of HE4 in a sample previously obtained from the subject; and, optionally, administering to the subject a therapeutically effective amount of a MUC16 antagonist.

Abstract: Example embodiments are directed to systems and methods for providing end of route navigation. In example embodiments, a network system identifies a destination of a route and retrieves a display template based on the destination. The display template provides guidelines for display of end of route content, whereby the display of the end of the route content is different than display of content during a middle of the route. The network system identifies, based on the display template, a display time to trigger the display of the end of the route content. The display time may be associated with a threshold distance to the destination. The network system monitors a location of a vehicle along the route and accesses end of route content. Responsive to detecting that the location of the vehicle is at the threshold distance to the destination, the network system causes presentation of the end of the route content on a device associated with the vehicle.

Abstract: The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a lung cancer; a cervical cancer; a breast cancer; a head and neck cancer; a liver cancer; a bladder cancer; a gastric cancer; an esophageal cancer; a pancreatic cancer; a kidney or renal cancer; a melanoma; an ovarian cancer; or a colorectal cancer). More specifically, the invention concerns the treatment of patients having cancer with an anti-TIGIT antagonist antibody, including treatment with an anti-TIGIT antagonist antibody in a combination therapy.

Abstract: This application discloses methods and compositions for use in treating cancer, including breast cancer (such as metastatic triple negative breast cancer, mTNBC), urothelial carcinoma, renal cell carcinoma, and liver cancer (hepatocellular carcinoma, HCC) with the combination of a PD-1 axis binding antagonist (e.g., a PD-L1 binding antibody such as atezolizumab) and an IL6 antagonist (e.g. an anti-IL6 receptor antibody such as tocilizumab), optionally further comprising a VEGF antagonist (e.g. an anti-VEGF antibody such as bevacizumab). Optionally, the patient has C-reactive protein (CRP) and/or IL-6 level(s) above the upper limit of normal. Optionally, the cancer is PD-L1 positive.

Abstract: A machine-learning model (e.g., a clustering model) may be used to predict a phenotype of a tumor based on expression levels of a set of genes. The set of genes may have been identified using a same or different machine-learning model. The phenotype may include an immune-excluded, immune-desert or an inflamed/infiltrated phenotype. A treatment strategy and/or treatment recommendation may be identified based on the predicted phenotype.